-
Pegloticase (trade name Krystexxa) is a
medication for the
treatment of severe, treatment-refractory,
chronic gout. It is a
third line
treatment in those...
-
Cinchophen M04AC51
Colchicine and
probenecid M04AX01
Urate oxidase M04AX02
Pegloticase "ATC (Anatomical
Therapeutic Chemical classification System) – Synopsis"...
-
hepatitis C, pegfilgrastim,
which is used to
treat neutropenia, and
pegloticase for the
treatment of gout.
There is
evidence demonstrating PEG-induced...
- monotherapy.
Pegloticase is an
option for the 3% of
people who are
intolerant to
other medications. It is a
third line agent.
Pegloticase is
given as an...
-
patients receiving chemotherapy. A
PEGylated form of
urate oxidase,
pegloticase, was FDA
approved in 2010 for the
treatment of
chronic gout in adult...
- diseases. Horizon's
portfolio includes Tepezza (teprotumumab),
Krystexxa (
pegloticase),
Actimmune (interferon gamma),
Duexis (ibuprofen + famotidine), Pennsaid...
-
peginesatide (USAN)
peginterferon alfa-2a (USAN)
peginterferon alfa-2b (INN)
pegloticase (USAN)
pegmusirudin (INN)
pegnartograstim (INN)
pegorgotein (INN) pegsitacase...
- in
adult patients on
dialysis (Affymax/Takeda Pharmaceuticals, 2012)
Pegloticase (Krystexxa) –
PEGylated uricase for the
treatment of gout (Savient, 2010)...
- was a New Jersey–based
biopharmaceutical company. Its lead product,
pegloticase, was a
biologic drug for
treatment resistant chronic gout,
which it marketed...
